- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| BIODESIX Aktie jetzt für 0€ handeln | |||||
| 14:12 | Morning Market Movers: CIIT, BDSX, AEHL, RAYA See Big Swings | 92 | AFX News | CANBERA (dpa-AFX) - At 7:30 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| 09:30 | Biodesix Stock Crashes Nearly 30% After Q3 Revenue Miss, Slashes 2026 Outlook | 4 | Benzinga.com | ||
| 09:24 | Biodesix expects $101M-$103M 2026 revenue while planning to exit 2026 with ~115 sales reps | 2 | Seeking Alpha | ||
| Do | BIODESIX INC - 8-K, Current Report | - | SEC Filings | ||
| 22.10. | Biodesix, Inc.: Biodesix to Report Third Quarter 2026 Financial Results on November 5, 2026 | 1 | GlobeNewswire (USA) | ||
| 19.10. | Biodesix, Inc.: American College of Chest Physicians Publishes New Framework for Lung Nodule Programs Recommending Biomarkers for Risk Stratification | 1 | GlobeNewswire (USA) | ||
| 19.10. | Biodesix adds digital diagnostics to lung testing platform | 1 | Investing.com | ||
| 19.10. | Biodesix, Inc.: Biodesix Adds Digital Diagnostics to Lung Pipeline, Creating New Growth Platform Combining Blood and Imaging Biomarkers | 1 | GlobeNewswire (USA) | ||
| 13.10. | Biodesix, Inc.: Biodesix to Present New Real-World Evidence Supporting Integration of Nodify Lung Testing into Routine Lung Nodule Care at CHEST 2026 | 5 | GlobeNewswire (USA) | ||
| 24.09. | Biodesix meldet Fortschritte bei MRD-Testprogrammen mit Bio-Rad und Thermo Fisher | 5 | Investing.com Deutsch | ||
| 24.09. | Biodesix, Inc.: Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring | 164 | GlobeNewswire (Europe) | LOUISVILLE, Colo., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced strategic progress in two collaborative programs for tumor-informed... ► Artikel lesen | |
| 14.09. | Biodesix, Inc.: Biodesix Quality and Regulatory Executive, Brianna Phillips, to speak at upcoming RAPS and SOCRA Annual Meetings | 2 | GlobeNewswire (USA) | ||
| 12.08. | Biodesix auf Canaccord Genuity Konferenz: Wachstum und Margen im Fokus | 1 | Investing.com Deutsch | ||
| 10.08. | Canaccord raises Biodesix stock price target on strong test volume | 2 | Investing.com | ||
| 06.08. | Biodesix maintains $108M-$114M 2026 revenue outlook while planning ~120 sales reps | 2 | Seeking Alpha | ||
| 05.08. | Biodesix, Inc.: Biodesix Announces Second Quarter 2026 Results and Highlights | 135 | GlobeNewswire (Europe) | Delivered $26.9 million in revenue, representing 34% growth in Q2 2026; Achieved 82% gross margin in Q2 2026; Maintained FY 2026 Revenue Guidance of $108-114 million, mid-point reflects 25% growth... ► Artikel lesen | |
| 05.08. | BIODESIX INC - 10-Q, Quarterly Report | - | SEC Filings | ||
| 05.08. | BIODESIX INC - 8-K, Current Report | 1 | SEC Filings | ||
| 22.07. | Biodesix, Inc.: Biodesix to Report Second Quarter 2026 Financial Results on August 5, 2026 | 1 | GlobeNewswire (USA) | ||
| 18.06. | Canaccord raises Biodesix stock price target to $27 on growth outlook | 4 | Investing.com |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IMMUNITYBIO | 7,310 | +2,38 % | ImmunityBio, Inc.: ImmunityBio Announces First Patients in Europe Treated with ANKTIVA Plus BCG for BCG-unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ | First patients treated in Germany and Austria, with commercial support from Accord Healthcare
Treatment milestone follows European Commission's February 2026 conditional marketing authorization... ► Artikel lesen | |
| BIOAGE LABS | 4,886 | -1,17 % | BioAge Labs GAAP EPS of -$0.73 misses by $0.09, revenue of $0.3M misses by $1.18M | ||
| ARCUTIS BIOTHERAPEUTICS | 27,000 | 0,00 % | Arcutis falls after Q3 earnings miss | ||
| KYMERA THERAPEUTICS | 128,21 | +0,07 % | Kymera International Appoints Willson Ropp as Chief Executive Officer | Experienced specialty materials executive brings more than 30 years of leadership experience across global manufacturing, operational excellence, business integration, and long-term value... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,500 | 0,00 % | Recursion Pharmaceuticals (NDQ:RXRX): Why Is Nvidia An Investor? Because Its AI Platform Could Change Drug Discovery, Or Could It? | ||
| ERASCA | 13,210 | -0,45 % | Tango Therapeutics, Inc.; Erasca, Inc.: Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015 | ||
| NURIX THERAPEUTICS | 14,805 | -0,24 % | Morning Market Movers: Curis, Inc., Darkiris, Amdocs, Nurix Therapeutics See Big Swings | NICOSIA (dpa-AFX) - At 8:05 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| MODERNA | 218,00 | +1,30 % | Moderna: WHO-Expertengremium empfiehlt Ebola-Impfstoff für Phase-2/3-Studie | Moderna hat bei der Entwicklung eines Impfstoffs gegen das Bundibugyo-Ebolavirus einen weiteren Schritt erreicht. Eine technische Beratergruppe der Weltgesundheitsorganisation WHO empfiehlt, den experimentellen... ► Artikel lesen | |
| QIAGEN | 45,220 | -0,11 % | Ihre wichtigsten Termine: Spannende Updates von: Moderna, Krones, Daimler Truck, Under Armour & Brookfield | © Foto: Bodo Schackow/dpaGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag Enthaltene Werte: CA29250N1050... ► Artikel lesen | |
| TYRA BIOSCIENCES | 20,890 | 0,00 % | Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with Dabogratinib | TYRA's mission is to make dabogratinib the clear first-line treatment choice for patients with LG IR NMIBC
Favorable safety and tolerability results support chronic... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 263,14 | +0,21 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| COGENT BIOSCIENCES | 29,540 | -0,14 % | Cogent Biosciences, Inc. - 8-K, Current Report | ||
| ENLIVEN THERAPEUTICS | 44,810 | +0,04 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update | Reached alignment with the FDA on the final design of the ENABLE-2 pivotal Phase 3 trial On track to initiate ENABLE-2 before year-end 2026 Strong balance sheet with $884 million in cash, cash equivalents... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 88,50 | +0,18 % | AstraZeneca, Cardiol Therapeutics, Kiniksa - Neue Hoffnung für Herzpatienten | Herz-Kreislauf-Erkrankungen gehören weltweit zu den größten medizinischen Herausforderungen. Während etablierte Pharmakonzerne Milliarden in neue Wirkstoffe und Künstliche Intelligenz investieren, entwickeln... ► Artikel lesen | |
| BEAM THERAPEUTICS | 25,800 | -0,27 % | Jones Trading initiates Beam Therapeutics stock coverage with buy rating |
Das Unternehmen BIODESIX INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 19,840 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIODESIX INC finden Sie auf Wallstreet Online.